Agilent Technologies (NYSE:A) had its price target decreased by Barclays from $85.00 to $76.00 in a report released on Thursday, BenzingaRatingsTable reports. The brokerage currently has an “equal weight” rating on the medical research company’s stock. Barclays‘s target price would suggest a potential upside of 4.17% from the stock’s current price.

Other research analysts also recently issued reports about the stock. Wells Fargo & Co began coverage on shares of Agilent Technologies in a research report on Tuesday, January 7th. They set an “overweight” rating and a $100.00 target price for the company. HSBC upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Wednesday, February 12th. UBS Group boosted their target price on shares of Agilent Technologies from $87.00 to $90.00 and gave the company a “neutral” rating in a research report on Wednesday, February 19th. Citigroup decreased their target price on shares of Agilent Technologies from $85.00 to $75.00 and set a “neutral” rating for the company in a research report on Friday, March 20th. Finally, Needham & Company LLC downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating and set a $85.00 target price for the company. in a research report on Monday, February 24th. Nine research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Agilent Technologies presently has a consensus rating of “Hold” and an average target price of $84.13.

Shares of NYSE:A traded up $3.96 on Thursday, hitting $72.96. 178,254 shares of the company were exchanged, compared to its average volume of 3,448,389. Agilent Technologies has a 1-year low of $61.13 and a 1-year high of $90.64. The stock’s 50 day moving average price is $77.67 and its 200 day moving average price is $79.67. The company has a current ratio of 1.64, a quick ratio of 1.27 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $20.75 billion, a P/E ratio of 30.37 and a beta of 1.33.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Tuesday, February 18th. The medical research company reported $0.81 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.81. Agilent Technologies had a net margin of 14.59% and a return on equity of 20.49%. The business had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.36 billion. During the same period in the previous year, the firm posted $0.76 earnings per share. The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. On average, equities analysts predict that Agilent Technologies will post 3.4 EPS for the current fiscal year.

In other news, SVP Dominique Grau sold 9,033 shares of the business’s stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $90.00, for a total transaction of $812,970.00. Following the completion of the sale, the senior vice president now owns 106,530 shares of the company’s stock, valued at $9,587,700. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael Tang sold 5,000 shares of the business’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $87.72, for a total transaction of $438,600.00. Following the sale, the senior vice president now directly owns 67,167 shares of the company’s stock, valued at approximately $5,891,889.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,527 shares of company stock valued at $1,544,402.

Hedge funds have recently added to or reduced their stakes in the company. Bowen Hanes & Co. Inc. grew its stake in shares of Agilent Technologies by 4.1% in the 4th quarter. Bowen Hanes & Co. Inc. now owns 3,310 shares of the medical research company’s stock valued at $282,000 after buying an additional 130 shares during the period. MainStreet Investment Advisors LLC grew its stake in shares of Agilent Technologies by 4.3% in the 4th quarter. MainStreet Investment Advisors LLC now owns 3,543 shares of the medical research company’s stock valued at $302,000 after buying an additional 145 shares during the period. Whittier Trust Co. grew its stake in shares of Agilent Technologies by 16.5% in the 4th quarter. Whittier Trust Co. now owns 1,108 shares of the medical research company’s stock valued at $95,000 after buying an additional 157 shares during the period. Regentatlantic Capital LLC grew its stake in shares of Agilent Technologies by 3.2% in the 4th quarter. Regentatlantic Capital LLC now owns 5,174 shares of the medical research company’s stock valued at $441,000 after buying an additional 162 shares during the period. Finally, Dorsey & Whitney Trust CO LLC grew its stake in shares of Agilent Technologies by 3.7% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 4,801 shares of the medical research company’s stock valued at $409,000 after buying an additional 173 shares during the period.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Featured Story: Trading Options- What is a Strangle?

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.